Stem Cell Activity and Viability Assays: Methods, Standards, and Applications

Stem cell activity assays provide quantitative measurement of cell viability, metabolic function, proliferative capacity, and clonogenic potential, forming the analytical foundation for quality control in cell therapy manufacturing, biobanking, and regenerative medicine research. This technical article reviews the principal sample types, measurable parameters, assay methodologies, and applicable international standards—such as ISO 10993-5, ISO 20391, and ASTM F2944—that govern stem cell activity determination in accredited laboratories.

Technical Overview

Stem cell activity determination refers to a coordinated set of analytical procedures used to quantify the functional status of stem cell populations. Rather than a single measurement, the term encompasses multiple complementary endpoints, including membrane integrity (viability), metabolic activity, proliferative capacity, clonogenic potential, and potency. Together, these parameters determine whether a stem cell preparation is biologically competent for its intended use, whether in clinical infusion, research experimentation, or product development.

Accurate activity measurement is critical because stem cell products are living therapeutics: their quality cannot be assured by physicochemical testing alone. A high total cell count with poor viability or exhausted proliferative capacity may render a product ineffective or unsafe. Consequently, activity assays serve as release criteria in cell therapy manufacturing, as stability indicators during storage and transport, and as acceptance criteria after cryopreservation and thawing.

Several international standards provide the methodological framework for these determinations. ISO 10993-5 establishes in vitro cytotoxicity testing principles based on metabolic activity, ISO 20391-1 and ISO 20391-2 govern general cell counting practices and the validation of counting methods, and ASTM F2944, ASTM F2998, and ASTM E2694 describe standardized protocols for MTT, XTT, and resazurin-based proliferation and viability assays, respectively. National standards, including GB standards for biotechnology and cell-based products, further define testing expectations in regional regulatory contexts. Accredited third-party laboratories routinely perform these assays under quality management systems aligned with ISO/IEC 17025 and, for clinical materials, under good manufacturing practice (GMP) controls.

Testing Samples

Mesenchymal Stem/Stromal Cells (MSCs)

MSCs derived from bone marrow, adipose tissue, umbilical cord (including Wharton's jelly), and dental pulp are the most frequently tested sample type. Typical submissions include fresh primary isolates, cultured cells at defined passages, and final formulated products. MSC activity testing generally combines viability measurement with identity confirmation (positive expression of CD73, CD90, and CD105; absence of CD34, CD45, CD14/CD11b, CD79a/CD19, and HLA-DR) and tri-lineage differentiation capability.

Hematopoietic Stem and Progenitor Cells (HSCs/HPCs)

Umbilical cord blood, mobilized peripheral blood apheresis products, and bone marrow aspirates are tested for both viability and functional competence. Because CD34+ enumeration is only meaningful when the cells are viable, CD34+ counting is performed with a viability dye so that the result reports the absolute number of viable CD34+ cells per unit volume, a key clinical release parameter.

Induced Pluripotent Stem Cells (iPSCs)

iPSC banks and research lines require rigorous activity and quality characterization, including viability after passaging or thawing, proliferation kinetics, pluripotency marker expression, and normal karyotypic stability. Residual differentiation and senescence are also monitored because they directly affect downstream activity results.

Cryopreserved Stocks and Final Products

Post-thaw samples represent a distinct and demanding testing category. Cryopreservation can inflict sublethal membrane and mitochondrial damage that is not fully visible immediately after thawing, so testing protocols often specify both immediate post-thaw measurement and delayed assessment after a short recovery culture period to reveal true functional survival.

Testing Items

Activity determination is typically structured around the following measurable endpoints, selected according to sample type and intended use:

• Cell viability percentage, based on membrane integrity or metabolic competence
• Absolute viable cell count and total nucleated cell count
• Metabolic activity quantified as absorbance, fluorescence, or luminescence signal relative to controls
• Proliferation capacity, expressed as population doubling level, population doubling time, or growth curve kinetics
• Colony-forming ability, including CFU-F frequency for MSCs and CFU-GM or CFU-C output for hematopoietic progenitors
• Apoptosis and necrosis distribution, reported as viable, early apoptotic, late apoptotic, and necrotic fractions
• Cellular senescence indicators, including senescence-associated beta-galactosidase activity
• Multi-lineage differentiation potential, verified through osteogenic, adipogenic, and chondrogenic induction with appropriate staining and gene or protein marker confirmation
• Viability-associated CD34+ cell enumeration for hematopoietic products

Testing Methods

Dye Exclusion and Membrane Integrity Assays

Trypan blue exclusion, performed with a hemocytometer or an automated cell counter, remains the reference method for rapid viability and cell counting and is the basis of the counting guidance in ISO 20391-1. Fluorescent intercalating dyes such as propidium iodide (PI) and 7-AAD enter only cells with compromised membranes, enabling dead-cell exclusion during flow cytometric acquisition. These methods are fast and inexpensive but measure membrane status only, which is why they are usually paired with functional assays.

Colorimetric Metabolic Activity Assays

MTT, MTS, XTT, WST-1, and water-soluble tetrazolium (CCK-8) reagents measure the reduction of tetrazolium salts by cellular dehydrogenases, producing a colorimetric signal proportional to metabolic activity. ASTM F2944 and ASTM F2998 standardize the MTT and XTT formats, and the MTT extract procedure specified in ISO 10993-5 is widely applied in cytotoxicity screening. These assays are well suited to high-throughput comparison of treatment conditions.

Fluorescence and Luminescence Assays

Resazurin (Alamar Blue-type) reduction assays convert a non-fluorescent substrate into fluorescent resorufin in metabolically active cells, offering excellent sensitivity and the advantage of being non-destructive, which permits repeated measurements on the same culture. ATP-based luminescent assays quantify the adenosine triphosphate present in viable cells, delivering a stable glow-type signal with a very broad linear range and short processing time.

Flow Cytometric Analysis

Multiparameter flow cytometry is the definitive method for distinguishing viability states. The Annexin V/PI combination separates viable, early apoptotic, and late apoptotic or necrotic populations. Fixable viability dyes, Ki-67 intracellular staining for cycling cells, and EdU or BrdU incorporation for DNA synthesis further extend the technique to proliferation assessment, all performed with calibrated instruments and appropriate compensation controls.

Clonogenic and Functional Assays

Colony-forming unit assays are the gold standard for functional proliferative capacity because they measure the ability of single cells to generate clones. CFU-F testing (fibroblast colonies from MSCs at limiting dilution) and hematopoietic CFU cultures in semisolid media directly demonstrate the self-renewal and differentiation capacity that metabolic assays cannot capture. Directed differentiation induction followed by lineage-specific staining completes the functional picture for MSC identity.

Label-Free and Automated Platforms

Impedance-based real-time cell analysis systems continuously monitor attachment, proliferation, and cytotoxic response without labels, generating kinetic profiles rather than single endpoints. Automated brightfield and fluorescence imaging platforms with algorithmic cell recognition increasingly support ISO 20391-2-aligned method validation by reducing operator variability in counting and viability scoring.

Quality Assurance and Compliance

For results to be defensible in regulatory or clinical contexts, activity assays must be performed within a controlled quality system. Method validation or verification should address specificity, linearity, range, accuracy, precision, and robustness in accordance with ISO 20391-2 expectations for counting methods. Reference materials, calibrated pipettes and counters, defined cell-seeding densities, and documented passage-number limits minimize variability. Accredited third-party laboratories operating under ISO/IEC 17025 accreditation, GMP-compliant facilities handling clinical-grade products, and GLP laboratories supporting preclinical studies each provide an appropriate compliance envelope depending on the intended use of the data. Chain-of-custody documentation, validated shipping conditions, and time-from-thaw to assay are critical pre-analytical variables that must be recorded with every submission.

Applications

Stem cell activity determination supports decision-making across the entire life cycle of cell-based products and research programs:

• Release testing and batch disposition for cell therapy products prior to administration
• Post-thaw quality assessment of cryopreserved clinical products and master or working cell banks
• Stability studies defining shelf life, storage temperature limits, and transport windows
• Process characterization and comparability studies after manufacturing changes or scale-up
• In vitro cytotoxicity and biocompatibility evaluation of medical device extracts and biomaterials under ISO 10993-5
• Drug screening programs assessing compound effects on stem cell survival and proliferation
• Cosmetic ingredient safety and efficacy substantiation using stem cell or progenitor cell models
• Research studies in developmental biology, tissue engineering, and regenerative medicine requiring standardized activity reporting

FAQ

What is the difference between cell viability and cell activity?

Viability describes whether cells are alive, typically judged by membrane integrity or the presence of metabolic function. Activity is a broader functional concept that includes viability but extends to proliferation rate, colony formation, differentiation potential, and potency. A sample can be largely viable yet functionally inactive, which is why combined testing panels are recommended.

Which viability threshold is typically required for clinical release?

Common release specifications require minimum viability of 70 to 90 percent depending on product type, route of administration, and regional regulatory expectations. Specific thresholds are defined by the product manufacturer's validated specifications and must be justified by clinical experience and stability data rather than adopted generically.

Which assay method should be selected for a given study?

The choice depends on sample type, cell number, turnaround requirement, and the question being asked. Trypan blue or 7-AAD exclusion suits rapid viability checks; resazurin or ATP luminescence suits sensitive quantitative comparison; flow cytometry with Annexin V/PI suits mechanistic apoptosis analysis; and CFU assays are preferred when functional proliferative capacity must be demonstrated.

Why is post-thaw viability sometimes lower when measured after a recovery period?

Some cells sustain mitochondrial and membrane damage during freezing that progresses to delayed death after thawing. Immediate measurement can therefore overestimate functional survival, and many protocols include a delayed assessment, typically after several hours of recovery culture, to reveal the truly viable fraction.

How should activity results be reported?

A complete report states the method used, viability percentage, absolute viable cell number, assay-specific quantitative values with units, controls and acceptance criteria, passage number and cell source, time from thaw to assay, and any deviations. Reports from accredited third-party laboratories should include accreditation identifiers and traceable calibration records to support regulatory submission.